FDA Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Resectable Early-Stage Non-small Cell Lung Cancer And No Known Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements
Author: Benzinga Newsdesk | August 16, 2024 05:18am